// App-Quantinova.ai

TPS1104 : Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer.

Researchers

Presenter

  • Erica L. Mayer

Principal Investigators

  • Seth Andrew Wander

  • Meredith M. Regan

  • Angela DeMichele

  • Andres Forero-Torres

  • Mothaffar F. Rimawi

  • Cynthia X. Ma

  • Massimo Cristofanilli

  • Carey K. Anders

  • Cynthia Huang Bartlett

  • Eric P. Winer

  • Harold J. Burstein

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Penn Medicine Abramson Cancer Center, Philadelphia, PA

  • University of Alabama at Birmingham, Birmingham, AL

  • Baylor College of Medicine, Houston, TX

  • Washington University School of Medicine, St. Louis, MO

  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University of North Carolina, Chapel Hill, NC

  • Pfizer Inc, Collegeville, PA

Locations

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Circulating tumor cells

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

  • Estrogen receptor alpha

  • Circulating DNA

Drug/Treatment

  • Fulvestrant

  • Palbociclib

  • Avelumab

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03147287

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved